Irene Kuter, D.Phil., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estradiol | 4 | 2014 | 1951 | 0.440 |
Why?
|
| Breast Neoplasms | 27 | 2022 | 21206 | 0.410 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2014 | 1536 | 0.340 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2012 | 410 | 0.330 |
Why?
|
| Anthracyclines | 4 | 2015 | 286 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2021 | 11878 | 0.260 |
Why?
|
| Troponin I | 3 | 2015 | 662 | 0.180 |
Why?
|
| Receptors, Estrogen | 3 | 2014 | 2253 | 0.140 |
Why?
|
| Taxoids | 3 | 2015 | 667 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2014 | 3556 | 0.130 |
Why?
|
| Doxorubicin | 6 | 2015 | 2234 | 0.130 |
Why?
|
| Cardiotoxins | 1 | 2015 | 36 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2015 | 197 | 0.120 |
Why?
|
| Echocardiography | 4 | 2015 | 5047 | 0.110 |
Why?
|
| Ventricular Function, Left | 3 | 2015 | 3941 | 0.110 |
Why?
|
| Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
| Receptor, erbB-2 | 6 | 2014 | 2603 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2013 | 1099 | 0.100 |
Why?
|
| Paclitaxel | 5 | 2005 | 1733 | 0.090 |
Why?
|
| Peroxidase | 1 | 2013 | 610 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 630 | 0.080 |
Why?
|
| Microbial Collagenase | 1 | 1989 | 112 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 9263 | 0.080 |
Why?
|
| Stroke Volume | 4 | 2015 | 5622 | 0.070 |
Why?
|
| Biological Factors | 1 | 1989 | 156 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 8647 | 0.070 |
Why?
|
| Carcinoma, Ductal | 1 | 2008 | 97 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10760 | 0.070 |
Why?
|
| Estrogens | 1 | 2014 | 1536 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1160 | 0.070 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 13676 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 952 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2005 | 348 | 0.070 |
Why?
|
| Heart Ventricles | 2 | 2015 | 3841 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2021 | 887 | 0.060 |
Why?
|
| Vinblastine | 2 | 2008 | 487 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2000 | 966 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 2907 | 0.060 |
Why?
|
| Female | 31 | 2022 | 397192 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 480 | 0.060 |
Why?
|
| Heart | 1 | 2015 | 4446 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3603 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2006 | 613 | 0.050 |
Why?
|
| Middle Aged | 19 | 2022 | 223492 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 9538 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2021 | 186 | 0.050 |
Why?
|
| Treatment Outcome | 9 | 2021 | 65371 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2002 | 355 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2015 | 1751 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 2145 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2005 | 1791 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 2006 | 715 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2012 | 2819 | 0.040 |
Why?
|
| Prognosis | 6 | 2015 | 30010 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 15662 | 0.040 |
Why?
|
| Humans | 31 | 2022 | 768166 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2001 | 327 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1999 | 151 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 797 | 0.040 |
Why?
|
| Fibroblasts | 1 | 1989 | 4176 | 0.040 |
Why?
|
| Adult | 19 | 2022 | 223646 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3514 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2002 | 1617 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 2055 | 0.040 |
Why?
|
| Integrins | 1 | 2002 | 842 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 1528 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 2735 | 0.030 |
Why?
|
| Fasting | 1 | 2022 | 1610 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 3800 | 0.030 |
Why?
|
| Mastectomy | 2 | 2014 | 1861 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1557 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2001 | 2914 | 0.030 |
Why?
|
| Time Factors | 5 | 2019 | 40218 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 9118 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2000 | 11244 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 6124 | 0.030 |
Why?
|
| Mammography | 1 | 2005 | 2433 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 1253 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1997 | 0.030 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2015 | 199 | 0.030 |
Why?
|
| Aged | 9 | 2022 | 171504 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2015 | 240 | 0.030 |
Why?
|
| Cyclophosphamide | 3 | 2005 | 2227 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15454 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1995 | 436 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 565 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2022 | 8741 | 0.020 |
Why?
|
| Prospective Studies | 5 | 2022 | 54926 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 560 | 0.020 |
Why?
|
| Europe | 1 | 2019 | 3436 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 8054 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 4912 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 59629 | 0.020 |
Why?
|
| Troponin C | 1 | 2011 | 48 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2015 | 5151 | 0.020 |
Why?
|
| Carcinoma | 1 | 2002 | 2332 | 0.020 |
Why?
|
| Piperidines | 1 | 1999 | 1667 | 0.020 |
Why?
|
| Pneumonia | 1 | 2001 | 2163 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 4568 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1995 | 537 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 6669 | 0.020 |
Why?
|
| Rabbits | 2 | 2002 | 4772 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2013 | 10101 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 6847 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39348 | 0.020 |
Why?
|
| North America | 1 | 2012 | 1289 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9419 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1989 | 826 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2005 | 4860 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4580 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 1525 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2661 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2022 | 81762 | 0.020 |
Why?
|
| Breast | 1 | 2015 | 1976 | 0.020 |
Why?
|
| Risk Factors | 4 | 2015 | 74944 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 22371 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3436 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4146 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1703 | 0.020 |
Why?
|
| Postmenopause | 1 | 2014 | 2518 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3428 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 100 | 0.010 |
Why?
|
| Palpation | 1 | 2005 | 166 | 0.010 |
Why?
|
| Disease Progression | 2 | 2019 | 13671 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 165 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3858 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 2819 | 0.010 |
Why?
|
| Integrin alpha6beta4 | 1 | 2002 | 30 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8890 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 10399 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2013 | 41754 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2002 | 863 | 0.010 |
Why?
|
| Cornea | 1 | 1989 | 1316 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 283 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1999 | 5717 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 13490 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2001 | 876 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 12800 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14783 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12077 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2916 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 1880 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6526 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13290 | 0.010 |
Why?
|
| Cause of Death | 1 | 2008 | 3721 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 36743 | 0.010 |
Why?
|
| Menopause | 1 | 2005 | 1656 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 21538 | 0.010 |
Why?
|
| Skin | 1 | 1989 | 4503 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1999 | 622 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 5315 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12840 | 0.010 |
Why?
|
| Cytokines | 1 | 1989 | 7453 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1652 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1989 | 19015 | 0.010 |
Why?
|
| Ribs | 1 | 1995 | 259 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 6004 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 23645 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 8542 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 24315 | 0.010 |
Why?
|
| Veins | 1 | 1995 | 769 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 1995 | 483 | 0.010 |
Why?
|
| United States | 1 | 2019 | 73039 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 2056 | 0.000 |
Why?
|
| Hodgkin Disease | 1 | 1995 | 1384 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 20227 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 14729 | 0.000 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1999 | 5341 | 0.000 |
Why?
|
| Animals | 2 | 2002 | 169246 | 0.000 |
Why?
|
| Lung | 1 | 2001 | 10099 | 0.000 |
Why?
|
| Inflammation | 1 | 2001 | 10873 | 0.000 |
Why?
|
| Male | 1 | 2015 | 364719 | 0.000 |
Why?
|
| Mice | 1 | 2002 | 82029 | 0.000 |
Why?
|